| Title |
The burden of rheumatoid arthritis and access to treatment: outcome and cost-utility of treatments
|
|---|---|
| Published in |
HEPAC Health Economics in Prevention and Care, December 2007
|
| DOI | 10.1007/s10198-007-0091-0 |
| Pubmed ID | |
| Authors |
G. Kobelt, B. Jönsson |
| Abstract |
Within the series of articles investigating the burden of rheumatoid arthritis (RA), this paper reviews the methods used for economic assessment of the RA treatments by HTA agencies and other bodies involved in cost-effectiveness analysis and the current status of the field. The overall methods, as well as the challenges, of cost-effectiveness analysis in RA are common to all chronic progressive diseases where much of the treatment benefit is delayed, while costs occur immediately. Also, as in all disabling diseases, much of the costs occur outside the health-care system, due to the rapid loss of work capacity and the need for informal care in the later stages of the disease. Thus, it is essential to adopt a long-term view and consider costs from the perspective of society, rather than the health-care service, to increase the relevance of the results for policy making. |
Mendeley readers
The data shown below were compiled from readership statistics for 67 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 1% |
| Colombia | 1 | 1% |
| Unknown | 65 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 15 | 22% |
| Student > Bachelor | 9 | 13% |
| Other | 7 | 10% |
| Professor | 3 | 4% |
| Student > Doctoral Student | 3 | 4% |
| Other | 12 | 18% |
| Unknown | 18 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 22 | 33% |
| Nursing and Health Professions | 6 | 9% |
| Economics, Econometrics and Finance | 5 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 3% |
| Agricultural and Biological Sciences | 2 | 3% |
| Other | 8 | 12% |
| Unknown | 22 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 September 2012.
All research outputs
#22,756,649
of 25,371,288 outputs
Outputs from HEPAC Health Economics in Prevention and Care
#1,211
of 1,303 outputs
Outputs of similar age
#162,827
of 167,401 outputs
Outputs of similar age from HEPAC Health Economics in Prevention and Care
#6
of 6 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,303 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.7. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 167,401 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one.